Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Therapy01:28

Drug Therapy

239
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
239
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

282
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
282
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

861
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
861
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

173
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
173
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

200
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
200
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

252
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
252

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Heart Failure Wired from Shock to Devices and Home: A New Era of Delivery.

US cardiology·2026
Same author

Gaps in Heart Failure Care: The Need for Effective Communication and Health Literacy-concordant Patient Education.

US cardiology·2025
Same author

The Timing for Primary Prevention for ICD in the Current Era of Pharmacotherapy.

Cardiac failure review·2025
Same author

Primary prevention ICD: essential safeguard or personalized selectivity?

European heart journal. Quality of care & clinical outcomes·2025
Same author

Pulmonary hypertension secondary to valvular heart disease: a state-of-the-art review.

Heart failure reviews·2023
Same author

Conversion to tacrolimus alone compared to full immunosuppression following cardiac transplantation (TACTFUL).

Clinical transplantation·2023

Related Experiment Video

Updated: Jan 14, 2026

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

601

Role of Device Therapy in Complementing Contemporary Medical Management.

Yoel Benarroch1,2, Natalie Tapaskar3, Amin Yehya4,5

  • 1Internal Medicine, Beth Israel Deaconess Medical Center Boston, MA.

US Cardiology
|October 20, 2025
PubMed
Summary

Novel device therapies offer new hope for heart failure (HF) patients, complementing traditional treatments. This review explores recent advancements in non-surgical devices, their trial outcomes, and mechanisms for improving HF care.

Keywords:
Heart failureautonomic modulatorsclinical trialsdevice therapypressure sensor monitoring devicesvalvular disease

More Related Videos

The Combined Use of Transcranial Direct Current Stimulation and Robotic Therapy for the Upper Limb
14:56

The Combined Use of Transcranial Direct Current Stimulation and Robotic Therapy for the Upper Limb

Published on: September 23, 2018

9.5K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.4K

Related Experiment Videos

Last Updated: Jan 14, 2026

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

601
The Combined Use of Transcranial Direct Current Stimulation and Robotic Therapy for the Upper Limb
14:56

The Combined Use of Transcranial Direct Current Stimulation and Robotic Therapy for the Upper Limb

Published on: September 23, 2018

9.5K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.4K

Area of Science:

  • Cardiology
  • Biomedical Engineering
  • Clinical Medicine

Background:

  • Heart failure (HF) is a complex clinical syndrome due to ventricular dysfunction.
  • Current management includes lifestyle changes, guideline-directed medical therapy, and addressing contributing factors.
  • Significant advancements in device therapies have emerged to improve HF morbidity and mortality.

Purpose of the Study:

  • To review the current landscape of novel non-surgical device therapies for heart failure.
  • To discuss the clinical trials, major outcomes, and mechanisms of action for these devices.
  • To inform clinicians about emerging therapies that complement existing medical management.

Main Methods:

  • Literature review of recent clinical trials and research on non-surgical HF devices.
  • Analysis of device mechanisms of action and targeted pathways.
  • Synthesis of data on efficacy and impact on HF morbidity and mortality.

Main Results:

  • Several novel non-surgical device therapies show promise in improving outcomes for heart failure patients.
  • These devices target various pathways involved in HF pathophysiology.
  • Evidence from trials demonstrates potential benefits in reducing morbidity and mortality.

Conclusions:

  • Novel non-surgical device therapies represent a rapidly evolving and important frontier in heart failure management.
  • These devices can effectively complement traditional medical therapies.
  • Clinicians must stay informed about these advancements to optimize patient care and outcomes.